All In Biotech

Drug Trial Radar · NCT02977715

JYNNEOS Smallpox Vaccine in Adult Healthcare Personnel at Risk for Mpox in the Democratic Republic of the Congo

An Open-Label Prospective Cohort Study of JYNNEOS Smallpox Vaccine in Adult Healthcare Personnel at Risk for Mpox in the Democratic Republic of the Congo

Last checked: Nov 19, 2026Latest source record: Apr 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,600

Actual

Start

Feb 23, 2017

Primary completion

Oct 31, 2025

Study completion Oct 31, 2025

Sponsor

Sponsor type
Federal agency
Collaborators
Ministry of Public Health, Democratic Republic of the Congo; Kinshasa School of Public Health; Bavarian Nordic
First posted
Nov 30, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Mpox is a febrile rash illness caused by the monkeypox virus. Its natural occurrence in the DRC puts healthcare and frontline workers at high risk of acquiring monkeypox virus infections that can prevent them from performing work duties, compromise the overall healthcare delivery in an already fragile system, and can result in death (case fatality estimates are approximately 10%). This is an open-label prospective cohort study in up to 1,600 eligible healthcare workers at risk of mpox infection through their daily work. The study will document mpox exposure and infection in participants while concurrently evaluating the immunogenicity and safety of the vaccine, JYNNEOS (also known as MVA-BN, IMVAMUNE®, IMVANEX), in healthcare personnel in the DRC. Participation in the study is voluntary and open to male and female healthcare personnel ages 18 years and older in Tshuapa Province in The Democratic Republic of Congo who are at risk of monkeypox virus infection through their daily work or laboratory personnel performing diagnostic testing for monkeypox virus.

Conditions

  • Monkeypox Virus Infection

Interventions

  • JYNNEOS (Liquid Formulation)Biological

    Two doses of attenuated live virus smallpox vaccine (JYNNEOS liquid formulation) administered on days 0 and 28 via subcutaneous injection (deltoid) (1 x 10\^8 Tissue Culture Infectious Dose 50 \[TCID50\] per 0.5 mL). A subset of participants will receive a booster dose.

  • JYNNEOS (Lyophilized Formulation)Biological

    Two doses of attenuated live virus smallpox vaccine (JYNNEOS lyophilized formulation) administered on days 0 and 28 via subcutaneous injection (deltoid) (1 x 10\^8 Tissue Culture Infectious Dose 50 \[TCID50\] per 0.5 mL). A subset of participants will receive a booster dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Monkeypox virus infectionTime frame: 2 years following initial vaccination
  2. Monkeypox virus exposureTime frame: 2 years following initial vaccination
  3. Orthopoxvirus Antibody ResponseTime frame: Days 0, 14, 28, 42, 180, 365, 545, and 730 days after the receipt of the first dose of vaccine; Days 3, 7, and/or 14, and through study completion (an average of 1 year) after receipt of single booster dose of vaccine.
  4. Distribution of Geometric Means Titers (GMTs)Time frame: Days 0, 14, 28, 42, 180, 365, 545, and 730 days after the receipt of the first dose of vaccine; Days 3, 7, and/or 14, and through study completion (an average of 1 year) after receipt of single booster dose of vaccine.
  5. Adverse event and serious adverse event informationTime frame: 2 years following initial vaccination; Day 3, 7, and/or 14 after receipt of single booster dose of vaccine

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tshuapa site

    Boende, Tshuapa, Democratic Republic of the Congo

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.